These findings establish RAS-pathway focused combinatorial CRISPR screening as a robust approach for identifying clinically actionable combination vulnerabilities and nominate FGFR signaling as a lineage-specific mediator of KRAS inhibitor resistance in PDAC.
R. Ebright, Yao He, Alan Zhang et al.· Cancer Research· 0 citations
Oncogenic KRAS drives >90% of pancreatic ductal adenocarcinoma (PDAC), and the pan-RAS inhibitor daraxonrasib doubles overall survival, but adaptive and acquired resistance limit the depth and duration of responses. To systematically map combination vulnerabilities, we developed RAS+, a digenic CRISPR knockout library...
R. Ebright, Yao He, Alan Zhang et al.· bioRxiv· 0 citations
Inhibiting pan-RAS(on) RAS-GTP with daraxonrasib, alone or in combination with a MEK inhibitor, provides a new strategy for the treatment of TNBC that inhibits RTK activation of the RAS-RAF-MEK-ERK pathway and tumor proliferation.
Michael P. East, J. Olivares-Quintero, D. Okumu et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.